Andrea Lobo,  —

UCB’s injection therapy Zilbrysq (zilucoplan) has gained approval in Canada for treating adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). The decision by Health Canada was supported by results from the Phase 3 RAISE trial (NCT04115293), in which the…

Treatment with nipocalimab led to significant reductions in disease severity among people with generalized myasthenia gravis (gMG), as assessed by a drop in the MG Activities of Daily Living (MG-ADL) score, according to top-line data from a pivotal Phase 3 trial. Findings from the trial, dubbed VIVACITY-MG3…

Treatment with Keytruda (pembrolizumab), an immune checkpoint inhibitor (ICI) used to treat cancer, may trigger myasthenia gravis (MG), according to a recent case report. The patient, a 73-year-old man with a previous history of skin and prostate cancer, developed symptoms of MG and myositis — a disease in which…

NMD Pharma announced the dosing of the first patient in a Phase 2b clinical trial of NMD670, its investigational oral therapy for generalized myasthenia gravis (gMG). The SYNAPSE-MG trial (NCT06414954), recently cleared by the U.S. Food and Drug Administration (FDA), is assessing the treatment’s safety and…

A greater reduction in disease severity a month after surgery to remove the thymus gland in myasthenia gravis (MG) patients without a thymus tumor is linked with lower disease recurrence, a study in China suggests. Patients with a reduction of at least 36.7% in the Quantitative Myasthenia Gravis score…

Blood levels of interleukin-41 (IL-41) — a signaling molecule involved in immune responses — are found to be significantly elevated in people with myasthenia gravis (MG), and associated with disease severity and inflammatory markers, a study from China reports. These findings indicate “IL-41 may be essential to the [disease]…

The 2024 National Patient Conference by the Myasthenia Gravis Foundation of America (MGFA) brought together more than 400 members of the myasthenia gravis (MG) community this week to educate participants about how to better manage their disease and raise awareness about treatments and clinical studies. “We are so…

People with myasthenia gravis (MG) — particularly those with more severe symptoms — are significantly hindered both in their ability to work and to engage in activities of daily living, a survey study reported. The impact of these impairments ranged from 13% to 40% across work time missed, as…

A young girl who showed unusual symptoms of ocular myasthenia gravis — persistent upper eyelid droopiness and outward deviation of the right eye — saw her symptoms ease after she received standard treatment, a case report shows. “This case emphasizes the diverse presentation of MG in ophthalmology, with ocular…

Timely rescue therapy use during a myasthenic crisis — a life-threatening complication of myasthenia gravis (MG) marked by severe breathing problems — can reduce mortality among patients. That’s according to new findings from researchers in China, who investigated risk factors associated with prolonged mechanical ventilation, which is commonly…